Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-06-22
2010-02-02
Tsang, Cecilia (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C568S020000
Reexamination Certificate
active
07655620
ABSTRACT:
Compositions and methods for decreasing the viability of cells, particularly aberrant non-healthy cells, and most particularly cancer cells, are disclosed. The primary agent that causes cell death is a toxic metal atom or ion. Embodiments of the invention provide compositions and methods to ensure that the toxic metal is directed to the desired cell or tissue. In one embodiment, the metal is bound to a sulfur-rich peptide or protein carrier containing a targeting moiety. Such metal-protein complex is targeted to the selected cells or tissues to enrich the cell or tissue site with the metal-containing peptide or protein molecules followed by administering a dithiocarbonyl which carries the metal from the protein inside the cells to induce cell death.
REFERENCES:
patent: 5783596 (1998-07-01), Medford et al.
patent: 6432452 (2002-08-01), Aylward
patent: 6756063 (2004-06-01), Kiss
patent: 2004/0171678 (2004-09-01), Kennedy
patent: 2004277379 (2004-03-01), None
patent: WO0038654 (2000-06-01), None
Nielson et al. “Independence of domains of metallothionein in metal binding,” J. Biol. Chem., 1985, 260, 8698-701.
Gale et al. “Effects of diethyldithiocarbamate and N-methyl-N-dithiocarboxyglucamine on murine hepatic cadmium-metallothionein in vitro. ” Res. Comm. Chem. Path. Pharm., 1985, 49, 423-34.
Theocharis et al. “Metallothionein expression in human neoplasia.” Histopathology, 2004, 103-18.
Gale et al. “Effects of Diethyldithiocarbamate and N-methyl-N-Dithiocarboxyglucamine on murine hepatic cadium-metallothionein in vitro” Research Communications in Chemical Pathology and Pharmacology, 1985, 49, 423-34.
International Search Report for PCT/US06/24608 mailed Sep. 13, 2007.
Penkowa, M. et al. Metallothionen Treatment Reduces Proinflammatory Cytokines IL-6 and TNF-alpha and Apoptotic Cell Death during Experimental Autoimmune Encephalomyelitis, Experimental Neurobiology, 2001, vol. 170, pp. 1-14.
Weitz et al., “Dissemination of tumor cells in patients undergoing surgery for colorectal cancer,” Clin. Cancer Res., vol. 4, pp. 343-348, 1998.
Futoshi et al., “Molecular detection of circulating cancer cells during surgery in patients with biliary-pancreatic cancer,” Am. J. Surg., vol. 177, pp. 475-479, 1999.
Camphausen, “Radiation therapy to a primary tumor accelerates metastatic growth in mice,” Cancer Res., vol. 61, pp. 2207-2211, 2001.
Curtis et al., “Leukemia risk following radiotherapy for breast cancer,” J. Clin. Oncol., vol. 7, pp. 21-29, 1989.
Shore,“Radiation-induced skin cancer in humans,” Med. Ped. Oncol., vol. 36, pp. 549-554, 2001.
Travis et al., “Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease,” J. Natl. Cancer Inst., vol. 24, pp. 182-192, 2002.
Volm, “Multidrug resistance and its reversal,” Anticancer Res. vol. 18, pp. 2905-2918, 1998.
Wolf et al., “Development of the novel biologically targeted anticancer agent Gefinitib: Determining the optimum dose for clinical efficacy,” Clin. Cancer Res., vol. 10, pp. 4607-4613, 2004.
Kägi et al., “Biochemistry of metallothionein,” Biochemistry, vol. 27, pp. 8510-8515, 1998.
Valls et al., “A new insight metallothionenin (MT) classification and evolution: The in vivo and in vitro metal binding features of homarus americanus recombinant MT,” J. Biol. Chem., vol. 276, pp. 32835-32843, 2001.
Va{umlaut over (s)}ák et al., “Metallothioneins: new functional and structural insights,” Current Opinion Chem. Biol., vol. 4, pp. 177-183, 2000.
Hunziker, “Metal removal from mammalian metallothioneins,” Methods in Enzymol, vol. 205, pp. 451-456, 1991.
Kojima et al., “Amino-acid sequence of equine renal metallothioenin-1B.,” Proc. Natl. Acad. Sci. USA, vol. 73, pp. 3413-3417, 1976.
Nordberg et al., “Separation of two forms of rabbit metallothionein by isoelectric focusing,” Biochem. J., vol. 126, pp. 491-498, 1972.
Comeau et al., “Gram scale purification and preparation of rabbit liver zinc metallothionein,” Preparative Biochem. vol. 22, pp. 151-164, 1992.
Satofuka et al., “Rapid method for detection and detoxification of heavy metal ions in water environments using phytochelatin,” J. Bioscience and Bioengineering, vol. 88, pp. 287-292, 1999.
Satofuka et al., “Metal-binding properties of phytochelatin-related peptides,” J. Inorganic Biochem., vol. 86, pp. 595-602, 2001.
Takagi et al., “Cellular toxicity of cadmium ions and their detoxification by heavy metal-specific plant peptides, phytochelatins, expressed in mammalian cells,” J. Biochem., vol. 131, pp. 233-239, 2002.
Mehra et al., “Glutathione-mediated transfer of Cu(I) into phytochelatins,” Biochem. J., vol. 307, pp. 697-705, 1995.
Toffoli et al., “Overexpression of folate binding protein in ovarian cancers,” Int. J. Cancer Pred. Oncol., vol. 74, pp. 193-198, 1997.
Weitman et al., “Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues,” Cancer Res., vol. 52, pp. 3396-3401, 1992.
Turek et al., “Endocytosis of folate-protein conjugates: ultrastructural localization in KB cells,” J. Cell Science, vol. 106, pp. 423-430, 1993.
Wang et al., “Folate-mediated targeting of antineoplastic drugs, imaging agents, and nucleic acids to cancer cells,” J. Controlled Release, vol. 53, pp. 39-48, 1998.
Atkinson et al., “Conjugation of folate via gelonin carbohydrate residues retains ribosomal-inactivating properties of the toxin and permits targeting to folate receptor positive cells” J. Biol. Chem., vol. 276, pp. 27930-27935, 2001.
Beckman et al., “Superoxide dismutase and catalase conjugated to polyethylene glycol increases endotheliar enzyme activity and oxidant resistance,” J.Biol. Chem., vol. 15, pp. 6884-6892, 1988.
Sawa et al., “Tumor-targeting chemotherapy by a xanthine oxidase-polymer conjugate that generates oxygen-free readicals in tumor tissues,” Cancer Res., vol. 60, pp. 666-671, 2000.
Farokhzad et al., “Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells,” Cancer Res., vol. 64, pp. 7668-7672, 2004.
Kukowska-Latallo et al., “Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of epithelial cancer,” Cancer Res., vol. 5, pp. 5317-5324, 2005.
Ibrahim et al., “Phase I and pharmacokinetic study of ABI-007, a cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel,” Clin Cancer Res., vol. 8, pp. 1038-1044, 2002.
Alexiou et al., “Locoregional Cancer treatment with magnetic drug targeting,” Cancer Res., vol. 60, pp. 6641-6648, 2000.
Gref et al., “Biodegradable long-circulating polymeric nanospheres,” Science, vol. 263, pp. 1600-1603, 1994.
Hong et al., “Isolation of a peptide for targeted drug delivery into human head and neck solid tumors,” Cancer Res., vol. 60, pp. 6551-6556, 2000.
Laakkonen et al., “A tumor-homing peptide with a targeting specificity related to lymphatic vessels,” Nature Medicine, vol. 8, pp. 751-755, 2002.
Burke et al., “Citengitide targeting of αυβ3integrin receptor synergizes with radioummunotherapy to increase efficacy and apoptosis in breast cancer xenografts,” Cancer Res., vol. 62, pp. 4263-4272, 2002.
Arap et al., “Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model,” Science, vol. 279, pp. 377-380, 1998.
Nilsson et al., “Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice,” Cancer Res., vol. 61, pp. 711-716, 2001.
Asai et al., “Suppression of tumor growth by novel peptides homing to tumor-derived new blood vessels,” FEBS Letters
Bradley Christina
Cancure Laboratories, LLC
Faegre & Benson LLP
Tsang Cecilia
LandOfFree
Use of one or more metal carriers to selectively kill... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of one or more metal carriers to selectively kill..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of one or more metal carriers to selectively kill... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4224803